Replies to post #17055 on Cytodyn Inc (CYDY)

[gestalt2]

Of course there is risk - it's a small biotech company with one product in clinical trial! Bitcoin looks conservative in comparison! This is a known thing from day one - Do you think that some how there is a way to make an investment like this with very little risk? My opinion is that there is nothing to give me concern about the trial or the company. Cytodyn has access to millions to keep going with the trials. Pro 140 is being injected in patients in phase 3 trials. there have been no safety concerns in the many years of different trials. the viral loads of patients have been shown to drop dramatically with no real side effects.

Keep in mind, typical biotech drug trials are full of failures and treatments that only work slightly better than existing drugs. The FDA's job is to make sure drugs don't get on the market that will kill the patient or not do anything that they claim they will do. Many drugs have a long list of side effects but are still FDA approved. Pro 140 has not show any of these issues.

HIV is a huge market, it is growing and the existing treatments will fail. Pro 140 is clearly a marketable product even with competition.

[gestalt2]

Be honest, would you feel better if cytodyn had no meeting planned with the FDA to discuss the PE data on there P3 combo trial? That would make me worried!

[JPG77]

Since the combo trial is apparently critical to the future of CYDY, there has to be some concern as long as the company has not shed any light on what is going on.

The company released a PR saying exactly what is going on. "The U.S. Food and Drug Administration has set a meeting on October 17 to discuss the next steps in CytoDyn’s efforts towards the analysis of primary efficacy endpoint and filing of a Biologics License Application for PRO 140."

That still confuses you? They didn't say the FDA set a meeting to discuss their concerns about the trial, or possibly extending it, but somehow you read that into it?